Home › Funds › BAKER BROS. ADVISORS LP › VRDN
BAKER BROS. ADVISORS LP position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 2,383,025 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$43.8M, representing 0.23% of its reported portfolio and ranking #40 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed VRDN holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's VRDN position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in VRDN in Q2 2025 at 1,744,406 shares (US$24.4M). The position peaked in Q4 2025 at 1,971,678 shares, worth US$61.4M. Across 5 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,383,025 shares valued at US$43.8M — an increase of 411,347 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.74M | $24.39M | New |
| Q3 2025 | 1.74M | $37.64M | Hold |
| Q4 2025 | 1.97M | $61.36M | Add |
| Q1 2026 | 1.97M | $38.57M | Hold |
| Q2 2026 | 2.38M | $43.78M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M sh · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M sh · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $66.00M · Q2 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Avoro Capital Advisors LLC 2.50M sh · $45.92M · Q2 2026
- Context Capital Management, LLC 40.75M sh · $43.82M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M sh · $39.22M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.79M sh · $32.93M · Q2 2026
- First Turn Management, LLC 1.67M sh · $30.68M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held VRDN?
BAKER BROS. ADVISORS LP has disclosed VRDN holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is BAKER BROS. ADVISORS LP's current position in VRDN?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.38M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $43.78M, representing 0.23% of its reported portfolio and ranking #40.
Has BAKER BROS. ADVISORS LP been buying or selling VRDN?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP increased its position in VRDN. The position peaked in Q4 2025 at 1.97M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.